Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.45 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.45 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | ACSS2 | Q9NR19 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20280108 | 0.99 | TLR7 (0.48) | TLR7ACSS2KDM4EPTGER4ALDH1A1 | |
| SCHEMBL29559474 | 0.99 | TLR7 (0.48) | TLR7ACSS2KDM4EPTGER4ALDH1A1 | |
| SCHEMBL23287291 | 0.88 | ACSS2 (0.51) | TLR7ACSS2KDM4EPTGER4ALDH1A1 | |
| SCHEMBL27478591 | 0.86 | ACSS2 (0.45) | TLR7ACSS2KDM4EALDH1A1PKM | |
| SCHEMBL25767043 | 0.85 | ACSS2 (0.46) | TLR7ACSS2KDM4EALDH1A1PKM | |
| SCHEMBL24265281 | 0.84 | ACSS2 (0.49) | ACSS2KDM4EALDH1A1PKMHTT | |
| SCHEMBL30676114 | 0.83 | ACSS2 (0.46) | ACSS2KDM4EHTTDRD2TBXA2R | |
| SCHEMBL20266433 | 0.83 | ACSS2 (0.46) | ACSS2KDM4EHTTDRD2TBXA2R | |
| SCHEMBL31413142 | 0.81 | ACSS2 (0.49) | ACSS2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL30474209 | 0.81 | TLR7 (0.48) | TLR7ACSS2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4219487-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119462622-A | GLP-1 receptor agonists and uses thereof | 辉瑞公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-110325530-B | GLP-1 receptor agonists and uses thereof | 辉瑞大药厂 | 2022-01-11 | — | — | CN | disclosed |
| US-20210047298-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10851081-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200255406-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2020-08-13 | — | — | US | disclosed |
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3555064-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018109607-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLA 865/4885GAA 888/4885DRD2 3291/4885 |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLA 748/4885GAA 723/4885DRD2 3464/4885 |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GLA 748/4885GAA 723/4885DRD2 3464/4885 |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLA 865/4885GAA 888/4885DRD2 3291/4885 |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | GLA 668/4885GAA 823/4885DRD2 3408/4885 |
| US-10851081-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLA 865/4885GAA 888/4885DRD2 3291/4885 |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLA 865/4885GAA 888/4885DRD2 3291/4885 |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | GLA 865/4885GAA 888/4885DRD2 3291/4885 |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLA 865/4885GAA 888/4885DRD2 3291/4885 |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLA 748/4885GAA 723/4885DRD2 3464/4885 |
| US-20210047298-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLA 865/4885GAA 888/4885DRD2 3291/4885 |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GLA 748/4885GAA 723/4885DRD2 3464/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | GLA 3276/4885GAA 973/4885DRD2 2519/4885 |
| US-20200255406-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLA 865/4885GAA 888/4885DRD2 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.